Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
AbCellera Biologics
ISIN CA00288U1066
|WKN A2QKXS
Market cap (in EUR)
1,055 m
Country
Canada
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
Healthcare Biopharmaceuticals Other Biopharmaceuticals Canada
Financials
Key metrics
| Market capitalisation, EUR | 1,055 m |
| EPS, EUR | -0.52 |
| P/B ratio | 1.3 |
| P/E ratio | 12.2 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 27 m |
| Net income, EUR | -151 m |
| Profit margin | -564.83% |
What ETF is AbCellera Biologics in?
There is 1 ETF which contains AbCellera Biologics.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.09% | Equity United States Health Care Biotech | 45 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.